Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
October 5, 2025Advanced Materials

Personalized Vaccination of Tumor‐Derived Antigens and STING Agonists for Specific Cancer Immunotherapy

View Full Paper
Ask AI
Bookmark
Share

Authors

NWNing WangXZXiaohui ZhangZGZhiliang Gao

Discussion

Loading...

Member takes

Overview

This approach activates specific anti-tumor responses using personalized antigen delivery and STING signaling.

Key Points

  • Personalized vaccines effectively utilize tumor-derived antigens to stimulate anti-tumor immune responses.
  • The use of hydrogels allows for controlled release of antigens and STING agonists, enhancing immunogenicity.
  • Self-assembled nanoparticles contribute to immunogenic cell death, aiding in the release of crucial antigens.
  • This strategy may prevent tumor progression and limit metastasis, paving the way for advanced cancer therapies.

Cite This Study

Wang et al. (2025) studied this question.

synapsesocial.com/papers/68e2537cd6d66a53c24744bfhttps://doi.org/10.1002/adma.202420325
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Supramolecular STING‐Hydrogel Spatiotemporally Boosts Tumor‐Derived Extracellular Vesicle‐Based Personalized Vaccine for Enhanced Cancer Immunotherapy2026
  2. 2Programming of in Situ Tumor Vaccines via Supramolecular Nanodrug/Hydrogel Composite and Deformable Nanoadjuvant for Cancer Immunotherapy2024 · 18 citations
  3. 3Assessing persistent antitumor immunity induced by tumor derived extracellular vesicle hydrogel vaccination without neoantigen identification2026
  4. 4Conformation-Transformable, Spiked Polypeptide Enables <i>In Situ</i> Cancer Vaccination via Conditional Antigen Capture and STING Activation2026 · 5 citations
  5. 5An Intracellular Gelated Macrophage-Based Vaccine for Tumor Immunotherapy2026 · 6 citations